ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

VAD

September 5, 2019
The January update of an expert panel from the American College of Chest Physicians on the expanding clinical entity of pulmonary hypertension, especially pertinent to the transplant community.
August 23, 2019
Excellent and brief summary of the debate on functional mitral regurgitation on mechanical support.
August 13, 2019
The translational value for cardiac transplantation of this prospective multi-centre clinical study of vasodilation in amyloidosis remains to be evaluated.
June 4, 2019
Left ventricular ejection fraction was not a predictor of outcomes after heart transplant, and was normal in all recipients at 1 year posttransplant. The reliance on generic transthoracic echocardiography for donor assessment may well be the Achilles heel of this retrospective case study.
April 23, 2019
This video demonstrates the right subclavian artery cut-down technique for implantation of an Impella® 5.0 as a short-term mechanical circulatory support device for the left heart.
March 26, 2019
The investigators published the final analysis of the MOMENTUM 3 trial comparing the fully magnetically levitated centrifugal continuous-flow HeartMate 3 pump to the mechanical-bearing axial continuous-flow HeartMate II pump.
February 26, 2019
Today, The Society of Thoracic Surgeons published the third annual Pediatric Interagency Registry for Mechanical Circulatory Support (PEDIMACS) report. Between Sep 19, 2012 and Dec 31, 2017, 423 patients (less than 19 years of age) in 30 hospitals were supported with 508 devices.
February 7, 2019
In the February issue of The Annals, The Society of Thoracic Surgeons published the first annual report after the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) joined the STS National Database in January 2018.  This report summarizes the outcomes in patients (≥19 years of age) undergoing durable MCS implant b
February 5, 2019
In a letter to healthcare providers, the US FDA summarized a recent evaluation of a postapproval study of the Abiomed Impella RP system. In clinical trials, 73% of patients survived 30 days after device explant, hospital discharge, or to definitive intervention. In the postapproval study, just over 17% of patients met this goal.
January 30, 2019
Garbade and colleagues compared outcomes reported during the European Conformity (CE) Mark clinical trial of the HeartMate 3 left ventricular assist device (LVAD)  to outcomes for patients treated since the device came to market.

Pages